As of Nov 19, 2026, 2 of 2 active firms rate LUNG a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
LUNG EPS & revenue forecast
EPS · NEXT QUARTER
$-0.26
Range $-0.29 – $-0.19 · 5 analysts · -21% YoY
Next period, 5 analysts expect Pulmonx Corp to earn $-0.26 a share (range $-0.29 – $-0.19), versus $-0.33 a year earlier. Full-year consensus is $-0.98, growing to $-0.92 the year after.
REVENUE · NEXT QUARTER
$22.5M
Range $22.0M – $22.9M · 5 analysts · +10% YoY
Revenue is expected to reach $22.5M (range $22.0M – $22.9M), +9.5% year-over-year. Full-year consensus is $91.0M, rising to $98.6M next year.
Top analysts covering Pulmonx Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LUNG.
#1
Joanne Wuensch
Citigroup · Rank #35
Neutral
$4.15+55.1% to target
Overall win rate
51%
+ Follow
#2
Jason Bednar
Piper Sandler · Rank #360
Neutral
$2.50-6.5% to target
Overall win rate
33%
+ Follow
#3
Frank Takkinen
Lake Street · Rank #514
Buy
$4.00+49.5% to target
Overall win rate
27%
+ Follow
#4
Jason Kolbert
D. Boral Capital · Rank #562
Buy
$14.00+423.4% to target
Overall win rate
22%
+ Follow
#5
LB
Larry Biegelsen
Wells Fargo
Neutral
$3.00+12.1% to target
Coverage
—
+ Follow
LUNG stock forecast FAQ
What is LUNG's average 12-month price target?+
The 2 active firms with a live target average $9.50 for Pulmonx Corp over the next 12 months, ranging from a $14.00 high to a $5.00 low, as of Nov 19, 2026.
Is LUNG stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for LUNG?+
The Street-high target is $14.00 (D. Boral Capital), and the Street-low is $5.00 (Canaccord Genuity). The average of all 2 active-firm targets is $9.50.
How many active Wall Street firms cover LUNG?+
2 active firms have a recognized rating on Pulmonx Corp as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering LUNG?+
Among analysts who currently cover LUNG, Joanne Wuensch of Citigroup has the strongest overall Quantellect track record (Rank #35). Their current call is Neutral with a $4.15 target.
What is Pulmonx Corp's projected EPS for next quarter?+
The consensus estimate is $-0.26 per share (range $-0.29 – $-0.19) across 5 analysts. Full-year EPS is projected at $-0.98, rising to $-0.92 the following year.
How much revenue is Pulmonx Corp expected to report next quarter?+
Consensus revenue is $22.5M (range $22.0M – $22.9M). Full-year revenue is projected at $91.0M, growing to $98.6M next year.
Have analysts been upgrading or downgrading LUNG lately?+
As of Nov 19, 2026, 2 of 2 active firms rate LUNG a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LUNG calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.